# A Study of LY2940680 in Small Cell Lung Cancer

> **NCT01722292** · PHASE1,PHASE2 · TERMINATED · sponsor: **Eli Lilly and Company** · enrollment: 26 (actual)

## Conditions studied

- Small Cell Lung Carcinoma

## Interventions

- **DRUG:** LY2940680
- **DRUG:** Carboplatin
- **DRUG:** Etoposide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01722292
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-01
- **Primary completion:** 2015-02
- **Final completion:** 2015-02
- **Target enrollment:** 26 (ACTUAL)
- **Why stopped:** Change in clinical strategy.
- **Last updated:** 2018-12-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01722292

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01722292, "A Study of LY2940680 in Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01722292. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*